Reversine suppresses oral squamous cell carcinoma via cell cycle arrest and concomitantly apoptosis and autophagy

Journal of Biomedical Science

Hau-Ren Chen³  Ming-Ko Chiang³  Ya-Ping Cheng³  Jeff Yi-Fu Chen¹  Wen-Tsai Ji³  Wei-Ching Wu³  Ying-Ray Lee² 

[1] Department of Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan;Department of Nursing, Min-Hwei College of Health Care Management, Tainan, Taiwan;Department of Life Science, Institute of Molecular Biology and Institute of Biomedical Science, College of Science, National Chung Cheng University, Min-Hsiung, Chia-Yi, Taiwan

关键词: oral squamous cell carcinoma (OSCC);    autophagy;    apoptosis;    cell cycle arrest;    Reversine;   

Others  :  825856
DOI  :  10.1186/1423-0127-19-9

 received in 2011-12-21, accepted in 2012-01-27,  发布年份 2012

【 摘 要 】

Background

The effective therapies for oral cancer patients of stage III and IV are generally surgical excision and radiation combined with adjuvant chemotherapy using 5-Fu and Cisplatin. However, the five-year survival rate is still less than 30% in Taiwan. Therefore, evaluation of effective drugs for oral cancer treatment is an important issue. Many studies indicated that aurora kinases (A, B and C) were potential targets for cancer therapies. Reversine was proved to be a novel aurora kinases inhibitor with lower toxicity recently. In this study, the potentiality for reversine as an anticancer agent in oral squamous cell carcinoma (OSCC) was evaluated.

Methods

Effects of reversine on cell growth, cell cycle progress, apoptosis, and autophagy were evaluated mainly by cell counting, flow cytometry, immunoblot, and immunofluorescence.

Results

The results demonstrated that reversine significantly suppressed the proliferation of two OSCC cell lines (OC2 and OCSL) and markedly rendered cell cycle arrest at G2/M stage. Reversine also induced cell death via both caspase-dependent and -independent apoptosis. In addition, reversine could inhibit Akt/mTORC1 signaling pathway, accounting for its ability to induce autophagy.

Conclusions

Taken together, reversine suppresses growth of OSCC via multiple mechanisms, which may be a unique advantage for developing novel therapeutic regimens for treatment of oral cancer in the future.

【 授权许可】

   
2012 Lee et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Ng SH, Yen TC, Liao CT, Chang JT, Chan SC, Ko SF, Wang HM, Wong HF: 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med 2005, 46:1136-1143.
• [2]Chung TT, Pan MS, Kuo CL, Wong RH, Lin CW, Chen MK, Yang SF: Impact of RECK gene polymorphisms and environmental factors on oral cancer susceptibility and clinicopathologic characteristics in Taiwan. Carcinogenesis 2011, 32:1063-1068.
• [3]Chen YK, Huang HC, Lin LM, Lin CC: Primary oral squamous cell carcinoma: an analysis of 703 cases in southern Taiwan. Oral Oncology 1999, 35:173-179.
• [4]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global Cancer Statistics. Ca-a Cancer Journal for Clinicians 2011, 61:69-90.
• [5]Trivedy CR, Craig G, Warnakulasuriya S: The oral health consequences of chewing areca nut. Addiction Biology 2002, 7:115-125.
• [6]Andreadis C, Vahtsevanos K, Sidiras T, Thomaidis I, Antoniadis K, Mouratidou D: 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer. Oral Oncology 2003, 39:380-385.
• [7]Okamura M, Kobayashi M, Suzuki F, Shimada J, Sakagami H: Induction of cell death by combination treatment with cisplatin and 5-fluorouracil in a human oral squamous cell carcinoma cell line. Anticancer Research 2007, 27:3331-3337.
• [8]Fu J, Bian M, Jiang Q, Zhang C: Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007, 5:1-10.
• [9]Seki A, Coppinger JA, Jang CY, Yates JR, Fang G: Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 2008, 320:1655-1658.
• [10]Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR: Aurora kinases as anticancer drug targets. Clinical Cancer Research 2008, 14:1639-1648.
• [11]Lens SMA, Voest EE, Medema RH: Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nature Reviews Cancer 2010, 10:825-841.
• [12]Vader G, Lens SM: The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008, 1786:60-72.
• [13]Steigemann P, Wurzenberger C, Schmitz MH, Held M, Guizetti J, Maar S, Gerlich DW: Aurora B-mediated abscission checkpoint protects against tetraploidization. Cell 2009, 136:473-484.
• [14]Qi G, Kudo Y, Ando T, Tsunematsu T, Shimizu N, Siriwardena SB, Yoshida M, Keikhaee MR, Ogawa I, Takata T: Nuclear Survivin expression is correlated with malignant behaviors of head and neck cancer together with Aurora-B. Oral Oncol 2010, 46:263-270.
• [15]Ben Khelifa M, Zouari R, Harbuz R, Halouani L, Arnoult C, Lunardi J, Ray PF: A new AURKC mutation causing macrozoospermia: implications for human spermatogenesis and clinical diagnosis. Mol Hum Reprod 2011, 17:762-768.
• [16]Kimmins S, Crosio C, Kotaja N, Hirayama J, Monaco L, Hoog C, van Duin M, Gossen JA, Sassone-Corsi P: Differential functions of the Aurora-B and Aurora-C kinases in mammalian spermatogenesis. Mol Endocrinol 2007, 21:726-739.
• [17]Meraldi P, Honda R, Nigg EA: Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 2004, 14:29-36.
• [18]Qi GY, Ogawa I, Kudo Y, Miyauchi M, Siriwardena BSMS, Shimamoto F, Tatsuka M, Takata T: Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Archiv 2007, 450:297-302.
• [19]Kao SY, Chen YP, Tu HF, Liu CJ, Yu AH, Wu CH, Chang KW: Nuclear STK15 expression is associated with aggressive behaviour of oral carcinoma cells in vivo and in vitro. J Pathol 2010, 222:99-109.
• [20]Dutertre S, Hamard-Peron E, Cremet JY, Thomas Y, Prigent C: The absence of p53 aggravates polyploidy and centrosome number abnormality induced by Aurora-C overexpression. Cell Cycle 2005, 4:1783-1787.
• [21]Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI: The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Research 2006, 66:7668-7677.
• [22]Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, et al.: PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007, 6:3158-3168.
• [23]Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop JM: Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci USA 2010, 107:13836-13841.
• [24]Mizushima N: Autophagy: process and function. Genes Dev 2007, 21:2861-2873.
• [25]Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, et al.: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004, 10:262-267.
• [26]Amabile G, D'Alise AM, Iovino M, Jones P, Santaguida S, Musacchio A, Taylor S, Cortese R: The Aurora B kinase activity is required for the maintenance of the differentiated state of murine myoblasts. Cell Death and Differentiation 2009, 16:321-330.
• [27]Lee EK, Bae GU, You JS, Lee JC, Jeon YJ, Park JW, Park JH, Ahn SH, Kim YK, Choi WS, et al.: Reversine Increases the Plasticity of Lineage-committed Cells toward Neuroectodermal Lineage. Journal of Biological Chemistry 2009, 284:2891-2901.
• [28]Mountzios G, Terpos E, Dimopoulos MA: Aurora kinases as targets for cancer therapy. Cancer Treatment Reviews 2008, 34:175-182.
• [29]D'Alise AM, Amabile G, Iovino M, Di Giorgio FP, Bartiromo M, Sessa F, Villa F, Musacchio A, Cortese R: Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. Mol Cancer Ther 2008, 7:1140-1149.
• [30]Hsieh TC, Traganos F, Darzynkiewicz Z, Wu JM: The 2,6-disubstituted purine reversine induces growth arrest and polyploidy in human cancer cells. Int J Oncol 2007, 31:1293-1300.
• [31]Labrada L, Bodelon G, Vinuela J, Benavente J: Avian reoviruses cause apoptosis in cultured cells: viral uncoating, but not viral gene expression, is required for apoptosis induction. J Virol 2002, 76:7932-7941.
• [32]Huang TT, Chen JY, Tseng CE, Su YC, Ho HC, Lee MS, Chang CT, Wong YK, Chen HR: Decreased GRP78 protein expression is a potential prognostic marker of oral squamous cell carcinoma in Taiwan. J Formos Med Assoc 2010, 109:326-337.
• [33]Crosio C, Fimia GM, Loury R, Kimura M, Okano Y, Zhou H, Sen S, Allis CD, Sassone-Corsi P: Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol 2002, 22:874-885.
• [34]Chefetz I, Holmberg JC, Alvero AB, Visintin I, Mor G: Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFkB pathway. Cell Cycle 2011, 10:2206-2214.
• [35]Li Y, Zhang ZF, Chen J, Huang D, Ding Y, Tan MH, Qian CN, Resau JH, Kim H, Teh BT: VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res 2010, 2:296-308.
• [36]Lin ZZ, Hsu HC, Hsu CH, Yeh PY, Huang CY, Huang YF, Chen TJ, Kuo SH, Hsu C, Hu FC, et al.: The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol 2009, 50:518-527.
• [37]Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 35:495-516.
• [38]Joza N, Susin SA, Daugas E, Stanford WL, Cho SK, Li CY, Sasaki T, Elia AJ, Cheng HY, Ravagnan L, et al.: Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 2001, 410:549-554.
• [39]Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, Daugas E, Geuskens M, Kroemer G: Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med 1996, 184:1331-1341.
• [40]Miramar MD, Costantini P, Ravagnan L, Saraiva LM, Haouzi D, Brothers G, Penninger JM, Peleato ML, Kroemer G, Susin SA: NADH oxidase activity of mitochondrial apoptosis-inducing factor. J Biol Chem 2001, 276:16391-16398.
• [41]Cande C, Cecconi F, Dessen P, Kroemer G: Apoptosis-inducing factor (AIF): key to the conserved caspase-independent pathways of cell death? J Cell Sci 2002, 115:4727-4734.
• [42]Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004, 30:193-204.
• [43]Luo J, Manning BD, Cantley LC: Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4:257-262.
• [44]Xu DR, Huang S, Long ZJ, Chen JJ, Zou ZZ, Li J, Lin DJ, Liu Q: Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells. Journal of Translational Medicine 2011., 9
• [45]Benten D, Keller G, Quaas A, Schrader J, Gontarewicz A, Balabanov S, Braig M, Wege H, Moll J, Lohse AW, et al.: Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 2009, 11:934-944.
• [46]Perreira M, Jiang JK, Klutz AM, Gao ZG, Shainberg A, Lu C, Thomas CJ, Jacobson KA: "Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem 2005, 48:4910-4918.
• [47]Anand S, Penrhyn-Lowe S, Venkitaraman AR: AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003, 3:51-62.
• [48]Martin-Ezquerra G, Salgado R, Toll A, Gilaberte M, Baro T, Alameda Quitllet F, Yebenes M, Sole F, Garcia-Muret M, Espinet B, et al.: Multiple genetic copy number alterations in oral squamous cell carcinoma: study of MYC, TP53, CCDN1, EGFR and ERBB2 status in primary and metastatic tumours. Br J Dermatol 2010, 163:1028-1035.
• [49]Fan LC, Chiang WF, Liang CH, Tsai YT, Wong TY, Chen KC, Hong TM, Chen YL: alpha-Catulin knockdown induces senescence in cancer cells. Oncogene 2011, 30:2610-2621.
• [50]Zhang L, Zhang S: ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin. J Obstet Gynaecol Res 2011, 37:591-600.
• [51]Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N: mTOR, translation initiation and cancer. Oncogene 2006, 25:6416-6422.
• [52]Sarbassov DD, Ali SM, Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005, 17:596-603.
• [53]Wang X, Proud CG: The mTOR pathway in the control of protein synthesis. Physiology (Bethesda) 2006, 21:362-369.
• [54]Jung CH, Ro SH, Cao J, Otto NM, Kim DH: mTOR regulation of autophagy. FEBS Lett 2010, 584:1287-1295.
• [55]Hippert MM, O'Toole PS, Thorburn A: Autophagy in cancer: Good, bad, or both? Cancer Research 2006, 66:9349-9351.
• [56]Thorburn A: Studying autophagy's relationship to cell death. Autophagy 2008, 4:391-394.
• [57]Gump JM, Thorburn A: Autophagy and apoptosis: what is the connection? Trends Cell Biol 2011, 21:387-392.
• [58]Yang Y, Xing D, Zhou FF, Chen Q: Mitochondrial autophagy protects against heat shock-induced apoptosis through reducing cytosolic cytochrome c release and downstream caspase-3 activation. Biochemical and Biophysical Research Communications 2010, 395:190-195.
• [59]Kondo Y, Kondo S: Autophagy and cancer therapy. Autophagy 2006, 2:85-90.
• [60]Notte A, Leclere L, Michiels C: Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochemical Pharmacology 2011, 82:427-434.
• [61]Soussi T, Lozano G: p53 mutation heterogeneity in cancer. Biochemical and Biophysical Research Communications 2005, 331:834-842.
• [62]Park WS, Lee JH, Shin MS, Park JY, Kim HS, Lee JH, Kim YS, Lee SN, Xiao WH, Park CH, et al.: Inactivating mutations of the caspase-10 gene in gastric cancer. Oncogene 2002, 21:2919-2925.
• [63]Soung YH, Lee JW, Kim SY, Jang J, Park YG, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH: CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Research 2005, 65:815-821.
• [64]Soung YH, Lee JW, Kim SY, Sung YJ, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH: Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas. Oncogene 2005, 24:141-147.
• [65]You J, He Z, Chen L, Deng G, Liu W, Qin L, Qiu F, Chen X: CH05-10, a novel indinavir analog, is a broad-spectrum antitumor agent that induces cell cycle arrest, apoptosis, endoplasmic reticulum stress and autophagy. Cancer Sci 2010, 101:2644-2651.